logo
Nvidia, National Science Foundation Partner to Create Open AI Models for US Scientists

Nvidia, National Science Foundation Partner to Create Open AI Models for US Scientists

Yahoo2 days ago
The US National Science Foundation (NSF) has secured significant investments from the private and public sectors for its Open Multimodal AI Infrastructure (OMAI) project. The Allen Institute for AI, known as Ai2, is leading the project, which will provide cutting-edge AI models for scientists nationwide. Nvidia has already committed $77 million to the new project.
The key to the OMAI project is that the large language models (LLMs) produced will be open source, freeing researchers from potential ties to private interests. At this stage of AI development, the hardware costs of training LLMs are outside the budgets of many research facilities. Those LLMs are generally not open source. (Even OpenAI isn't entirely open source, despite its name.) Ai2 plans to fill that gap with the OMAI project by producing LLMs geared towards literature and scientific data.
'These tools will enable America's researchers and developers to process and analyze research faster, generate code and visualizations, and connect new insights to past discoveries, accelerating breakthroughs across materials science, biology, energy, and more,' the NSF wrote in a statement.
Ai2 was founded by the late Paul Allen, a Microsoft co-founder who donated considerable sums to further science research. The investment in Ai2's OMAI project gives Ai2 a massive boost in funding and hardware.
Credit: Nvidia.
Nvidia isn't the only organization contributing to the OMAI project. The NSF is providing $75 million, bringing the initial investment to $152 million. The Trump administration recently created an AI Action Plan, which prioritizes the US's 'global dominance in artificial intelligence.'
'Bringing AI into scientific research has been a game changer,' said Brian Stone of the NSF. 'NSF is proud to partner with Nvidia to equip America's scientists with the tools to accelerate breakthroughs. These investments are not just about enabling innovation; they are about securing US global leadership in science and technology and tackling challenges once thought impossible.'
The $152 million will also help the OMAI project support universities in Hawai'i, New Hampshire, New Mexico, and Washington. The project already has partnerships with Cirrascale Cloud Services and SuperMicro. Cirrascale will handle hardware infrastructure management.
As you'd expect from a hardware company, Nvidia is providing its HGX B300 systems, which are loaded with Nvidia Blackwell chips and designed for AI uses. According to Nvidia, the HGX B300 features 8 Blackwell Ultra SXM GPUs and up to 2.3TB of memory. The OMAI project hasn't indicated yet how many HGX B300 systems will be involved.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Yahoo

time2 minutes ago

  • Yahoo

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5. On August 8, Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29, while keeping a Strong Buy rating on the shares. This sentiment followed Relay Therapeutics' Q2 2025 results, where OpEx was down 16% sequentially following strategic cost-cutting initiatives. Relay Therapeutics reported a net loss of $70.4 million, or $0.41 per share, in Q2 2025, which was an improvement compared to the net loss of $92.2 million, or $0.69 per share, in Q2 2024. Revenue for the quarter was $0.7 million, which was an increase from zero revenue in the same period last year. A chemist arranging containers of compounds, ready for the commercialization process. This quarter also featured the initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 in Q2 2025. At the 2025 American Society for Clinical Oncology/ASCO Annual Meeting, updated interim data from the Phase 1b study for RLY-2608 were presented. In addition to oncology, Relay Therapeutics is continuing to execute its ongoing Phase 1 clinical trial for vascular malformations. Relay Therapeutics Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth
Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Yahoo

time2 minutes ago

  • Yahoo

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Clover Health Investments Corp. (NASDAQ:CLOV) is one of the most promising penny stocks under $5. On August 7, Canaccord lowered the firm's price target on Clover Health to $4.10 from $4.50, while keeping a Buy rating on the shares. The firm said the company reported solid Q2 2025 results, but the insurance benefit expense ratio came in higher than expected, which was of some concern. In Q2, the company's Medicare Advantage membership grew by over 30% year-over-year, and the insurance revenue increased by 34% to $470 million. Clover Health Investments' technology-first care model, which includes the Clover Assistant platform, showed a 15% reduction in hospitalizations and an 18% reduction in readmissions for patients with chronic obstructive pulmonary disease/COPD. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company is now well-positioned for future growth with a 4-star payment year in 2026, which is expected to provide a financial tailwind. Clover Health is also expanding its technology platform to other risk-bearing entities, potentially opening up additional revenue streams. Clover Health Investments Corp. (NASDAQ:CLOV) is a company that provides medicare advantage plans in the US. It operates Clover Assistant, which is a software platform to execute strategy by enabling physicians to detect, identify, and manage chronic diseases earlier than they otherwise could. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

RBC Capital Cuts Algoma Steel (ASTL) PT to C$8 Following Q2 Net Loss
RBC Capital Cuts Algoma Steel (ASTL) PT to C$8 Following Q2 Net Loss

Yahoo

time2 minutes ago

  • Yahoo

RBC Capital Cuts Algoma Steel (ASTL) PT to C$8 Following Q2 Net Loss

Algoma Steel Group Inc. (NASDAQ:ASTL) is one of the most promising penny stocks under $5. On July 31, RBC Capital lowered the firm's price target on Algoma Steel to C$8 from C$10, while maintaining a Sector Perform rating on the shares. Prior to this decision, the company released its Q2 2025 earnings. Algoma Steel Group reported a net loss of $110.6 million, which was a sharp contrast to the net income of $6.1 million in the prior year's quarter. Adjusted EBITDA was a loss of $32.4 million, which reflected a negative margin of 5.5%. This was driven by a 10.5% year-over-year decline in steel revenue to $534 million, as well as lower steel shipments of 472,000 net tons, down 6.2% from the previous year. A factory worker operating a machine that processes steel products. The average net sales realization was $1,132 per ton, a decrease from $1,187 per ton in the prior year period, while the average cost per ton of steel products sold increased by 7% year-over-year to $1,144. A major factor contributing to the financial downturn was $64 million in direct tariff costs on outbound steel shipments to the US, which is a market now effectively closed to Canadian steel producers due to prohibitive tariffs. The company also reported ending the quarter with inventories valued at $736 million, a decrease from $800 million in the prior year quarter. Algoma Steel Group Inc. (NASDAQ:ASTL) produces and sells steel products in Canada, the US, and internationally. While we acknowledge the potential of ASTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store